Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DCTHNASDAQ:LUCDNASDAQ:PDEXNYSE:RVP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDCTHDelcath Systems$15.34-1.9%$14.07$7.17▼$18.23$534.23M0.95387,687 shs316,414 shsLUCDLucid Diagnostics$1.29-1.5%$1.30$0.68▼$1.80$139.56M1.31583,986 shs744,546 shsPDEXPro-Dex$39.56-3.3%$50.32$16.84▼$70.26$129.01M0.1731,998 shs24,785 shsRVPRetractable Technologies$0.65-5.9%$0.70$0.56▼$1.21$19.49M1.3969,169 shs61,123 shs10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDCTHDelcath Systems-1.92%-6.35%-0.84%+21.94%+113.95%LUCDLucid Diagnostics-1.53%0.00%+0.78%-7.19%+72.23%PDEXPro-Dex-3.32%-7.81%-8.72%-20.34%+100.81%RVPRetractable Technologies-5.90%-4.41%-14.45%-10.94%-43.14%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationDCTHDelcath Systems3.6919 of 5 stars3.55.00.00.03.72.50.6LUCDLucid Diagnostics3.3492 of 5 stars3.65.00.00.02.81.70.6PDEXPro-Dex3.2176 of 5 stars3.52.00.00.02.22.51.9RVPRetractable Technologies1.2439 of 5 stars0.03.00.00.01.93.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDCTHDelcath Systems 3.00Buy$24.0056.45% UpsideLUCDLucid Diagnostics 3.20Buy$3.55175.19% UpsidePDEXPro-Dex 3.00Buy$56.0041.56% UpsideRVPRetractable Technologies 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest PDEX, RVP, DCTH, and LUCD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/6/2025LUCDLucid DiagnosticsAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$7.50 ➝ $7.755/27/2025PDEXPro-DexAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$54.00 ➝ $56.005/23/2025DCTHDelcath SystemsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$24.00 ➝ $29.005/15/2025LUCDLucid DiagnosticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$2.00 ➝ $2.005/14/2025LUCDLucid DiagnosticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$3.00 ➝ $3.004/21/2025LUCDLucid DiagnosticsAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$7.00 ➝ $7.504/11/2025LUCDLucid DiagnosticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$3.00 ➝ $3.003/26/2025LUCDLucid DiagnosticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$2.00 ➝ $2.003/25/2025LUCDLucid DiagnosticsBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$2.003/24/2025LUCDLucid DiagnosticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$2.50 ➝ $3.00(Data available from 6/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDCTHDelcath Systems$53.85M9.92N/AN/A$0.72 per share21.31LUCDLucid Diagnostics$4.17M33.44N/AN/A($0.47) per share-2.74PDEXPro-Dex$64.12M2.01$1.14 per share34.81$9.76 per share4.05RVPRetractable Technologies$33.75M0.58$0.01 per share48.25$3.31 per share0.20Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDCTHDelcath Systems-$47.68M-$0.50N/AN/AN/A-150.70%-338.16%-104.02%8/4/2025 (Estimated)LUCDLucid Diagnostics-$52.67M-$1.34N/AN/AN/A-1,069.87%N/A-123.54%8/11/2025 (Estimated)PDEXPro-Dex$2.13M$2.8019.6819.20N/A11.06%21.68%12.40%N/ARVPRetractable Technologies-$7.01M-$0.77N/A∞N/A-41.11%-17.15%-9.33%N/ALatest PDEX, RVP, DCTH, and LUCD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025DCTHDelcath Systems$0.10$0.03-$0.07$0.03$16.83 million$19.80 million5/1/2025Q3 2025PDEXPro-Dex$0.47$0.98+$0.51$0.98$17.70 million$17.41 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDCTHDelcath SystemsN/AN/AN/AN/AN/ALUCDLucid DiagnosticsN/AN/AN/AN/AN/APDEXPro-DexN/AN/AN/AN/AN/ARVPRetractable TechnologiesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDCTHDelcath SystemsN/A1.341.03LUCDLucid DiagnosticsN/A1.181.14PDEXPro-Dex0.332.581.44RVPRetractable Technologies0.018.575.92Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDCTHDelcath Systems61.12%LUCDLucid Diagnostics74.01%PDEXPro-Dex15.28%RVPRetractable Technologies7.58%Insider OwnershipCompanyInsider OwnershipDCTHDelcath Systems17.40%LUCDLucid Diagnostics6.80%PDEXPro-Dex47.50%RVPRetractable Technologies57.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDCTHDelcath Systems6034.83 million26.24 millionOptionableLUCDLucid Diagnostics70108.19 million54.12 millionNo DataPDEXPro-Dex1403.26 million1.71 millionNot OptionableRVPRetractable Technologies24029.94 million13.47 millionOptionablePDEX, RVP, DCTH, and LUCD HeadlinesRecent News About These Companiesretractable technologies appoints new auditor after mergerJune 8, 2025 | investing.comThomas J. Shaw Buys 86,014 Shares of Retractable Technologies, Inc. (NYSE:RVP) StockMay 17, 2025 | insidertrades.comRetractable Technologies, Inc. Results for the Period Ended March 31, 2025 | RVP Stock NewsMay 15, 2025 | gurufocus.comRetractable Technologies, Inc. Results for the Period Ended March 31, 2025May 15, 2025 | businesswire.comRetractable Technologies, Inc. (NYSE:RVP) CEO Buys $10,037.25 in StockMay 15, 2025 | insidertrades.comThomas J. Shaw Purchases 22,620 Shares of Retractable Technologies, Inc. (NYSE:RVP) StockMay 7, 2025 | insidertrades.comInsider Buying: Retractable Technologies, Inc. (NYSE:RVP) CEO Buys 16,165 Shares of StockApril 24, 2025 | insidertrades.comInsider Buying: Retractable Technologies, Inc. (NYSE:RVP) CEO Purchases 33,524 Shares of StockApril 15, 2025 | insidertrades.comLittle Elm's Retractable Technologies announces 7% workforce reduction due to tariffsApril 11, 2025 | starlocalmedia.comRetractable Technologies cuts workforce to reduce reliance on China amid trade warApril 11, 2025 | drugdeliverybusiness.comRetractable Technologies announces 7% workforce reductionApril 11, 2025 | markets.businessinsider.comRetractable Technologies, Inc. Announces Reduction in WorkforceApril 10, 2025 | businesswire.comRetractable Technologies, Inc. Reports Results for 2024March 28, 2025 | businesswire.comRetractable Technologies, Inc. Declares Dividends to Series II and III Class B Preferred Stock ShareholdersMarch 28, 2025 | investing.comRetractable Technologies, Inc. Declares Dividends to Series II and III Class B Preferred Stock ShareholdersMarch 28, 2025 | businesswire.comThomas J. Shaw Buys 18,227 Shares of Retractable Technologies, Inc. (NYSE:RVP) StockFebruary 5, 2025 | insidertrades.comRetractable Technologies CEO Thomas Shaw acquires $14,082 in stockFebruary 4, 2025 | msn.comRetractable Technologies, Inc. (NYSE:RVP) CEO Acquires $10,080.45 in StockJanuary 29, 2025 | insidertrades.comRetractable technologies CEO Thomas Shaw acquires shares worth $10,105January 28, 2025 | msn.comRetractable Technologies, Inc. (NYSE:RVP) CEO Purchases $22,707.36 in StockJanuary 24, 2025 | insidertrades.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePDEX, RVP, DCTH, and LUCD Company DescriptionsDelcath Systems NASDAQ:DCTH$15.34 -0.30 (-1.92%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$15.49 +0.15 (+0.98%) As of 06/13/2025 06:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.Lucid Diagnostics NASDAQ:LUCD$1.29 -0.02 (-1.53%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$1.30 +0.00 (+0.39%) As of 06/13/2025 07:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.Pro-Dex NASDAQ:PDEX$39.56 -1.36 (-3.32%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$39.79 +0.23 (+0.58%) As of 06/13/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Pro-Dex, Inc. designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets. It also provides engineering, quality, and regulatory consulting services; and manufactures and sells rotary air motors to various industries. The company's products are used in hospitals, medical engineering labs, scientific research facilities, and high-tech manufacturing operations. Pro-Dex, Inc. was founded in 1978 and is headquartered in Irvine, California.Retractable Technologies NYSE:RVP$0.65 -0.04 (-5.90%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$0.66 +0.01 (+1.23%) As of 06/13/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Retractable Technologies, Inc. designs, develops, manufactures, and markets safety syringes and other safety medical products for the healthcare profession in the United States, rest of North and South America, and internationally. The company offers VanishPoint insulin syringes; tuberculin, insulin, and allergy antigen syringes; small diameter tube adapters; blood collection tube holders; allergy trays; IV safety catheters; Patient Safe syringes and Luer Caps; VanishPoint blood collection sets; EasyPoint needles; and VanishPoint autodisable syringes. It distributes its products through general line and specialty distributor; international distributors; and a direct marketing network. Retractable Technologies, Inc. was incorporated in 1994 and is headquartered in Little Elm, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/09 - 06/13 Alphabet Enters a Bull Market: Is It Time to Buy? Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones Super Micro Computer Stock: 2 Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Ignore the Noise—Samsara Stock Is Still a Strong Buy Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
